As the April 12 shareholder vote for the proposed Bristol-Myers Squibb Co./Celgene Corp. merger draws closer, SEC documents have offered a clearer picture of how the deal announced Jan. 3 came to be, including talks that began in early 2017, a late effort by Celgene to get a competing bid, and Bristol’s successful 11th-hour gambit to reduce its upfront cash commitment in the transaction.
Ultimately, Celgene agreed to be acquired by Bristol in a deal valued at $102.43 per share, with its stock closing...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
